Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.

Beqvez was Pfizer's first gene therapy, stemming from an alliance with Spark Therapeutics (now part of Roche) more than a ...

Beqvez was Pfizer's first gene therapy, stemming from an alliance with Spark Therapeutics (now part of Roche) more than a ...

US pharma giant Pfizer has ended all development and commercialization activities relating to fidanacogene elaparvovec, a ...

Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...

The Global Recombinant DNA Technology Market was valued at approximately USD $$ billion in 2022 and is expected to grow at a healthy CAGR of over $% from 2023 to 2030. Recombinant DNA Technology ...

The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...

Cavazzoni stepped down from her role as head of the FDA’s main drug review office in mid-January. She will succeed Aida ...

Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...

The global Cell and Gene Therapy Market is valued at $20.5 billion in 2024 and is projected to reach a value of $128.8 ...

Summit Therapeutics (SMMT) enters a clinical trial collaboration to evaluate its cancer drug, ivonescimab, in combination with Pfizer (PFE) antibody drug conjugates across multiple solid tumor ...

Scientists are exploring gene editing as a way to correct trisomy at the cellular level. Using CRISPR-Cas9, researchers ...